Abstract:Fei Qi, Yimeng Gao, Hongzhong Jin Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People's Republic of China Correspondence: Hongzhong Jin, Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People's Republic of China, Tel +86-10-69151500, Email The application of biologics such as anti-tumor necrosis factor (TNF) has shown great efficacy in livedoid vasculopathy (LV). However, new biological options need to be identified for those with a high tuberculosis reactivation risk. In this study, we evaluated the efficacy of anti-17A biologics for LV therapy. Two patients with LV who were irresponsive to traditional anticoagulation therapy were studied at the outpatient dermatology clinic of Peking Union Medical College Hospital. All patients received anti-17A biological therapy for at least two–four weeks. Both patients reported an exacerbation of the skin lesions, which might indicate that the IL-17 pathway plays a critical role in LV pathogenesis. Keywords: livedoid vasculopathy, biologic therapy, TNF-alpha, IL-17, atrophied blanched Livedoid vasculopathy (LV) is a rare condition characterized by extensive patterns of discolored skin (livedo reticularis), pigmented purpuric dermatosis-like lesions, painful ulcers, and scar tissue with a silvery appearance. 1 Microscopically, it is marked by focal microvascular thrombosis within the lumina without a significant inflammatory infiltrate. 2 However, the pathogenesis of LV remains unclear. Recent studies have revealed hypercoagulability, encompassing microcirculatory and thrombotic events, with an inflammatory mechanism having a supporting role. 1 Most patients with LV demonstrate recurrent episodes and exacerbations, especially during summer. The agonizing ulcers caused great pain, which severely lowered the patients' quality of life and immobilized a few patients. 3 There are no first-line or standard treatment for livedoid vasculopathy has been found. Currently, the most popular treatment option for livedoid vasculopathy is anticoagulant monotherapy such as rivaroxaban. A certain degree of curative effect has been observed for other treatments of livedoid vasculopathy, including vitamin supplementation, UV light, thrombolytics, intravenous immunoglobulins, anabolic steroids, and combination therapy. 4 Introduction of biologics has shed light on most chronic dermatological diseases. In a previous study, we found that using anti-tumor necrosis factor (TNF) medications in combination with anticoagulants had a significant positive impact on resolving LV lesions and managing pain in patients with uncontrolled LV ulcers. 5 However, for individuals at high risk of tuberculosis reactivation or those who do not respond well to anti-TNF therapy, we are still searching for more effective treatment options. Studies have reported that inhibition of TNF alpha partially limits the pro-coagulative effect of IL-17A that confers in other autoimmune diseases the higher cardiovascular risk. 6 In this report, we present two cases of LV that did not respond to standard treatments and worsened after receiving anti-17A biological treatment (Table 1). The study was approved by the Ethics Committee of Peking Union Medical College Hospital. Written informed consent for publication was obtained from two patients. Table 1 Patient Characteristics and Response to Anti-17A Therapy A 41-year-old male, previously in good health, presented with recurring painful ulcers on his lower limbs and feet during the summer months over a span of 7 years. He was diagnosed as livedoid vasculopathy by his clinical appearance and the further confirmed the diagnosed by both skin biopsy and the recommended diagnostic pathway. 2 He experienced significant improvement in symptoms during the summer when he began taking a daily dose of 30 mg prednisone, which was later tapered to a maintenance dose of 10 mg. Unfortunately, in summer, his condition deteriorated, and prednisone therapy at 30 mg had a minimal impact. To alleviate the symptoms, an additional 10 mg of rivaroxaban was administered, resulting in partial relief from pain, although a few new ulcers emerged (Figure 1). Figure 1 Patient in Case 1 before Secukinumab 300mg treatment. During his visit, he complained of recent cough. We ordered a CT scan that demonstrated s -Abstract Truncated-

Recalcitrant lipodermatosclerosis with ulceration treated with oxandrolone and pentoxifylline

FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid

The Effect of Oxandrolone on the Healing of Chronic Pressure Ulcers in Persons With Spinal Cord Injury

Efficacy and safety of pentoxifylline for chronic venous leg ulcers: study protocol for a multicenter randomized controlled trial in China (ESPECT study)

Efficacy and Safety of Pentoxifylline for Venous Leg Ulcers: An Updated Meta-Analysis

Lenalidomide and Dexamethasone in Scleromyxedema: A Case Report of Long-Term Efficacy and Challenges in a 54-Year-Old Patient

Anti-Interleukin 17A Biologic Therapy Attempts on Livedoid Vasculopathy: A Report of Case Series

Successful Treatment of Keloid With Fractionated Carbon Dioxide (CO2) Laser and Laser-Assisted Drug Delivery of Triamcinolone Acetonide Ointment in an African-American Man

Full-Length Transcriptome Sequencing Analysis of Differentially Expressed Genes and Pathways After Treatment of Psoriasis With Oxymatrine

Therapy of livedo vasculitis with pentoxifylline

Self-initiated lifestyle interventions lead to potential insight into an effective, alternative, non-surgical therapy for mitochondrial disease associated multiple symmetric lipomatosis

Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin

Coexistent psoriasis and bullous pemphigoid responding to mycophenolate mofetil monotherapy

Short-term efficacy of oxaliplatin as interventional therapy for liver cancer, and its effect on serum CD163 and AFU

Efficacy and Safety of Oxymatrine in the Treatment of Patients with Erythrodermic Psoriasis

The Combined Use of Platelet-Rich Plasma Clot Releasate and Allogeneic Human Umbilical Cord Mesenchymal Stem Cells Rescue Glucocorticoid-Induced Osteonecrosis of the Femoral Head

Use of fat transfer to treat a chronic, non-healing, post-radiation ulcer: a case study

Real‐life experience of using pegylated liposomal doxorubicin in primary cutaneous T‐cell lymphomas

Enhanced Chemo‐Immunotherapy Strategy Utilizing Injectable Thermosensitive Hydrogel for The Treatment of Diffuse Peritoneal Metastasis in Advanced Colorectal Cancer

Non-invasive Oxygen-Ozone therapy in treating digital ulcers of patients with systemic sclerosis

A Severe Inflammatory Acne Was Successfully Cleared by Topical Photodynamic Therapy Mediated with 5-Aminolevulinic Acid in an Refractory Aplastic Anemia Female Patient: a Case Report